Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Friedman DM, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon CK, Cuneo B, Cohen R, Masson M, Wainwright BJ, Zahr N, Saxena A, Izmirly P, Buyon JP. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation Arrhythmia And Electrophysiology 2020, 13: e008686. PMID: 32907357, PMCID: PMC7668319, DOI: 10.1161/circep.120.008686.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCardiotoxicityDrug Administration ScheduleDrug MonitoringElectrocardiographyFemaleFetal BloodFetal HeartGestational AgeHeart BlockHeart RateHumansHydroxychloroquineInfantInfant, NewbornMalePredictive Value of TestsPregnancyRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBlood levelsSSA/Ro antibodiesHistorical healthy controlsHydroxychloroquine blood levelsCord blood levelsCongenital heart blockSystemic lupus erythematosusTrimester of pregnancyEfficacy of hydroxychloroquineCoronavirus disease-19Electrocardiographic QT intervalCOVID-19 studiesPostnatal ECGRo antibodiesIndividual pregnanciesLupus erythematosusQTc prolongationAntiviral therapyHeart blockClinical efficacyRheumatic conditionsDrug exposureMaternal useCord bloodDisease-19Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal Of The American College Of Cardiology 2020, 76: 292-302. PMID: 32674792, PMCID: PMC7394202, DOI: 10.1016/j.jacc.2020.05.045.Peer-Reviewed Original ResearchConceptsCongenital heart blockPrimary outcomeSecondary outcomesEndocardial fibroelastosisHeart blockRecurrence of CHBSSA/Ro-positive mothersAnti-SSA/RoMacrophage Toll-like receptorToll-like receptor antagonistsCutaneous neonatal lupusRo-positive mothersGestational weeks 10Toll-like receptorsFetal cardiac diseaseNeonatal lupusPositive mothersSecondary preventionSkin rashPrevious pregnancyTreat analysisClinical evidenceRecurrence rateReceptor antagonistOptimal approach